Topics

FDA signs off on IND for Avrobio's Gaucher disease gene therapy study

05:09 EST 15 Jan 2020 | SmartBrief

The investigational new drug application submitted by Avrobio to advance its Phase I/II study assessing its experimental gene -More

Original Article: FDA signs off on IND for Avrobio's Gaucher disease gene therapy study

NEXT ARTICLE

More From BioPortfolio on "FDA signs off on IND for Avrobio's Gaucher disease gene therapy study"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...